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Summary 
Recently we reported evidence that the nucleocapsid (NC) of  rabies virus is a V[38-specific ex- 
ogenous superantigen (SAg) in humans and a V[36-specific SAg in BALB/c mice. NC was also 
found to stimulate rabies vaccination by enhancing the rabies neutralizing antibody response. In 
this study, we tested the hypothesis that the stimulating effect of NC and its SAg properties are 
linked. To do this, we studied the effect of  rabies SAg on the immune response to an unrelated 
antigen,  the  influenza virus,  and  compared  the  response  in  two  congenic  strains  of mice, 
BALB/c and BALB/D2. BALB/c mice are rabies SAg responsive, whereas BALB/D2 mice are 
not responsive to SAg activation by rabies NC because they lack the SAg recognition element, 
the V[36 T cell receptor. In BALB/c mice, coinjection of rabies SAg with inactivated influenza 
virus resulted in a rapid and long-term increase in (a) the titres of influenza virus-specific anti- 
bodies  (IgG and IgM), including protective hemagglutination-inhibiting antibodies,  (b) anti- 
gen-specific proliferation and,  (c) IL-2 and IL-4 secretion by lymph node lymphocytes, when 
compared to mice that received influenza virus only. In contrast, in BALB/D2 mice, neither 
antibody nor lymphocyte responses were stimulated.  Moreover, during establishment of the 
primary response, the increase in influenza-primed T  cells was mainly restricted to those bear- 
ing a V~6 TCR. These data establish  that rabies SAg can stimulate both T  and B  cell-specific 
responses to an unrelated antigen, depending on expression of the SAg target (V[36 T lympho- 
cytes). This is the first report linking NC adjuvant properties with its SAg mechanism. 
T 
he molecular basis  of antigen-specific T  lymphocyte 
activation is the recognition of a specific peptide anti- 
gen by the r  chains of the T  cell receptor (TCR). To be 
recognized by the TCR, antigens first need to be cleaved 
by the antigen-presenting cells  (APC)  into small  peptides 
before being associated with the major histocompatibility 
complex (MHC) molecules through their peptide-binding 
groove and presented on the surface of APC. Specific rec- 
ognition  of the  peptide-MHC  complex by  the  TCR  is 
generated by somatic  recombination  of the  variable  ele- 
ments of the TCR ot and [3 chains. As a consequence, the 
frequency of T  cells activated by one peptide is extremely 
low  (1  in  104 tO  106).  Superantigens  (SAg) 1 are a  special 
class of antigens that, unlike peptides, bind outside the pep- 
tide  groove, and  cross-link the  outer faces  of the  MHC 
class  II  molecules and  the  variable  [3  (V13) chains  of the 
TCR  (1).  SAg are recognized almost without MHC  re- 
striction. They do not require antigen processing and target 
specifically one or several of the 20 or so V[3 family T lym- 
phocytes. Thus, the frequency ofa T cell response to a SAg 
1Abbreviations used in this  paper: HA, hemagglutinin; HI, Hemagglutination 
inhibition; HIU, HI unit; LNC, lymph node cells; MAM, Mycoplasma ar- 
thritidis mitogen; MMTV, mouse mammary tumor virus; NC, nucleo- 
capsid; SAg, superantigen. 
is extremely high (up to 1 in 102). SAg activation is charac- 
terized by a  sudden  expansion of the T  cells  bearing the 
correct V[3, and secretion of large amounts  of cytokines. 
When the APC  are B  lymphocytes, the molecular bridge 
formed by the SAg between T  and B lymphocytes may in- 
duce unusual T-B interactions and trigger B  cells to pro- 
duce  antibodies.  When  T  and/or B  lymphocytes are  al- 
ready engaged  in  an  antigen-specific response,  it  can be 
assumed  that  SAg  could  amplify the  antigen-specific re- 
sponse either directly because of the T-B interaction or in- 
directly because  of cytokine secretion  (2).  Theoretically, 
one could exploit the SAg ability to enhance an associated 
immune response and use SAg as an adjuvant. 
SAg are  encoded not  only by bacteria  or mycoplasma 
but also  by viruses,  in particular exogenous and endoge- 
nous  mouse  mammary  tumor retroviruses  (MMTV)  and 
most recently, the rabies virus (3, 4). With regard to the ra- 
bies virus, we have already established that the viral nucleo- 
capsid (NC),  and its main component the N  protein, be- 
have as V[38-specific exogenous SAg in humans (4, 5) and 
as V[36-specific SAg in BALB/c mice but not in congenic 
BALB/D2 mice, which lack the V[36 T  cells responsive to 
rabies  SAg (6).  Additionally, the NC  can induce cognate 
T-B interactions in vitro since, in human tonsillar cells, we 
found that the NC  triggers T  lymphocytes to secrete cy- 
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in the presence of T  cells (5),  Previous studies established 
that NC could enhance the immune response to rabies vac- 
cination or to an unrelated peptide (7, 8). We hypothesized 
that  rabies  SAg  would  stimulate  the  immune  response 
against an unrelated vaccinal antigen and could therefore be 
used as an adjuvant. In this study, we tested whether rabies 
SAg stimulated the immune  response  to  influenza in two 
congenic strains of mice,  BALB/c  and BALB/D2,  which 
differ only in their ability to respond to rabies SAg. 
Our results show that the rabies NC  does in fact stimu- 
late an antibody response directed against a simultaneously 
injected non-rabies antigen, and that its SAg properties are 
responsible of the NC  adjuvant capacity, This report is the 
first direct evidence establishing that a SAg can be used suc- 
cessfully as an adjuvant, and the first description of an ex- 
planatory mechanism. 
Materials and Methods 
Reagents, Virus, Cells, and Culture Medium.  NC was prepared 
from rabies virus-infected hamster kidney cell (mycoplasma free) 
lysates and partially purified through CsC1 gradients as previously 
described (9). 
Inactivated influenza virus (310 p,g HA/ml), purified influenza 
virus (8 mg/ml) used for ELISA and for in vitro lymphocyte pro- 
liferation, and hyperimmune rabbit serum (16,000-32,000 HIU/ 
ml), were prepared with  the  influenza NIB16  virus,  A-HIN1 
strain,  a  hybrid between  X31  and A/Taiwan/1/86  (gifts  from 
Pasteur M&ieux S~mms et Vaccins, Marcy l'Etoile, France). Rat 
anti-mouse IL-4 mAb (capture antibodies BVD4-1Dll  and bi- 
otinylated detection antibodies BVD6-24G2),  and biotinylated 
rat anti-mouse V[36 and V1310 mAbs (RR4-7  and B21.5)  were 
purchased from PharMingen (San Diego, CA). HRP-conjugated 
streptavidin and biotin-conjugated sheep  anti-mouse whole  Ig 
were  purchased from Amersham  (Amersham,  UK).  2.2'-azino- 
di-[3-ethyl-benzthiazolin-sulfonate-6] (ABTS) was obtained from 
Boerhinger  Mannheim  (Indianapolis, IN).  [3H]Thymidine was 
purchased from Dupont de Nemours (Les Ulis, France). Recep- 
tor destroying enzyme (RDE) (cholera vibrio neuraminidase) was 
purchased from Sigma Chemical Co. (St. Louis, MO). 
Lymphocytes from popliteal lymph nodes (LN) were cultured 
in RPMI  1640  (GIBCO BRL,  Cergy-Pontoise, France), 2 mM 
t-glutamine, 10 -2 mM 13-mercaptoethanol  and 100 U/ml genta- 
micin, supplemented with 10% fetal calf serum. The IL-2-depen- 
dent CTLL-2 cell line (10) was maintained in the same medium 
supplemented with  10%  condition medium of ConA-stimulated 
rat splenocytes. 
Mice.  Two types of mice were used in these experiments: fe- 
male BALB/c (H-2  a, I-E+, and VI33-, V[35-, and VI311- de- 
leted)  purchased from Janvier  (St-Berthevin, France)  and  con- 
genic  BALB/D2  (H-2  a,  I-E+,  and  VI33-,  V135-,  V[311-, 
V~6-, V~7-, V~8.1 -, and V[39- deleted), a gift from Martine 
Brulay-Rosset (ViUejuif, France). 
Immunization  of Mice.  To measure the putative rabies SAg ad- 
juvant effect on influenza immunization, 8-wk-old BALB/c or 
BALB/D2 mice were injected i.p. with 100 I~1 of inactivated in- 
fluenza virus containing 5 p,g HA alone or with 20 I~g of SAg. A 
secondary immunization was given by the same route with 2 p,g 
HA 3 mo (= 90 d) after priming (see Fig. 2).  Blood was taken 
from the retro-orbital-sinus every week for 12 wk after the prim- 
ing and for 3 wk after each secondary immunization. For in vitro 
proliferation assays and cytokine production, BALB/c and BALB/ 
D2 mice were injected in the footpad with 50 ~i of inactivated 
influenza virus alone (5 I~g HA) or with influenza virus and SAg 
(20 Izg). Control mice were injected with 50 I~1 pyrogen-free sa- 
line solution or SAg alone. Mice were killed after 1, 3, 5, or 7 d, 
pophteal LN were removed aseptically, and LN cells (LNC) pre- 
pared for culture assays. 
Ig Production.  Anti-influenza and anti-NC antibody concen- 
trations were determined from mice sera by ELISA. Briefly, puri- 
fied influenza virus or NC (200 ng/well) was coated overnight on 
Maxisorb  Immunolon  plates  (Nunc,  Rosktiide,  Denmark)  in 
0.05  M  carbonate buffer,  pH 9.6,  at 4~  After blocking with 
10% normal serum (rabbit, goat, or sheep according to the species 
of the  detection antibody)  in  phosphate  buffered saline  (PBS) 
with Ca  2+ Mg  a+ containing 0.05% Tween 20 (PBS-Tween), se- 
rial threefold dilutions of serum, starting with a  1/300  dilution, 
were  incubated  at  37~  for 90  min.  Plates were  washed  with 
PBS-Tween,  and  then  incubated  with  biotin-conjugated anti- 
mouse whole Ig. Biotinylated anti-mouse Ig were detected with 
streptavidin-peroxidase conjugate and then ABTS. Optical densi- 
ties were measured at 405 nm using a photometer. Results were 
expressed in arbitrary units/ml (AU/ml) using serum ofhyperim- 
munized mice as reference for influenza-specific antibodies and a 
NC-specific mAb, PVA-3, (9), for NC-specific antibodies. 
Hemagglutination Inhibition Antibody  Titrations.  Sera were pre- 
treated with RDE for 18 h at 37~  and with hen erythrocytes for 
30 min at room temperature to eliminate nonspecific inhibitors of 
hemagglutination.  Hemagglutination  inhibition  (HI)  titrations 
were performed in 96-well round-bottom polystyrene microtiter 
plates. Serial twofold dilutions of mouse sera in 50 I*l of PBS, pH 
7.3, were mixed with four hemagglutination units of virus in 50 
t*1 of  PBS and incubated for 60 min at room temperature. A 0.5% 
(vol/vol) hen erythrocyte suspension in PBS was added to the vi- 
res-antibody mixture in a volume of 50 gd, and plates were incu- 
bated for 60 rain at room temperature. Rabbit influenza-specific 
serum was used as a standard. HI antibody titers were expressed in 
HI unit per ml (HIU/ml) as the reciprocal of the highest serum 
dilution inhibiting four hemagglutination units of virus. 
Limiting Dilution Assay of Purified Vfl T Cells.  VI36  or V[310 T 
lymphocytes were  purified from  the  popliteal LN  of mice  in- 
jected 7 d before with SAg +  influenza or influenza alone. LNC 
were incubated 30 rain on ice with biotin-conjugated anti-V[36 
or anti-V~10 mAb in PBS, 5 mM EDTA, 1% BSA, washed and 
then incubated 15 min with streptavidin-coated magnetic micro- 
beads  (MACS;  Miltenyi  Biotech,  Gladbach,  Germany).  Cells 
linked to the beads were firstly retained in a column through a 
powerful  magnetic  field  (VarioMACS;  Miltenyi Biotech)  and 
then washed out. Harvested cells were over 95% V[36 or V[~10 
positive as assayed by cytofluorimetry analysis. Different concen- 
trations of purified V[3 T  cells (120  X  103 cells/well to 2  ￿  103 
cells/well) were distributed in 100  gtl of medium in wells of 96- 
well microtiter plate containing 50  I-d of irradiated (3,000  rad) 
splenocytes of nonimmunized BALB/c used as feeders (5  ￿  105 
cells/well) and 50 p~l of influenza antigen (final concentration of 
2 p,g/ml).  20  replicates were  seeded for each  concentration  of 
cells and controls. Controls consisted of feeder cells alone culti- 
vated with influenza antigen. The 24 h supernatants were assayed 
for IL-2 production by CTLL-2 proliferation. Wells were consid- 
ered positive when  counted cpm were three times higher than 
the  average cpm  counted in  controls.  Frequency of influenza- 
responsive cells were estimated by regressing (least square method) 
the log of the percentage of non-responder wells against the cell 
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and ranges (confidence interval 95%)  were then estimated using 
the reciprocal of the cell number corresponding to 37% of non- 
responder wells (11).  Differences between  frequencies of each 
treatment group were assessed by a one way variance analysis test 
(ANOVA). 
Cell Proliferation.  LNC at 2 ￿  10  s cells/well in a final volume 
of 200  la,1 were cultured in 96-well plates at 37~  in 5% CO2, 
alone or with serial dilutions ofanti-CD3 antibody or UV-inacti- 
rated influenza virus (0.01-10 ttg/rnl). After 72 h, the cells were 
pulsed with 1 ~Ci/well of [SH]thymidine and harvested 8 h later 
with a Mach III harvester (Wallac, Turku, Finland). Radioactivity 
(cpm) was measured using a Micro-13 6-detector PLUS (Wallac). 
Intedeukin Assays.  IL-2, and IL-4 productions were measured 
in 50  ttl of supernatants of either total LNC  or V[3 T  purified 
cultures. IL-2 was measured in 24-h supematants by a biological 
assay using tL-2--dependent CTLL-2 cell lines. Results were ex- 
pressed m cpm, representing [3H]thymidine incorporation by 10  ~ 
CTLL-2 cells cultured 24 h  in the presence of supernatants. In 
each test, serial dilution of  an IL-2 reference were assayed as con- 
trol. IL-4 was measured in 48-h supernatants, by capture ELISA. 
Briefly, capture anti-mouse IL-4 rat antibody was coated over- 
night on Maxisorb Immunolon plates in 0.05 M carbonate buffer, 
pH  9.6,  at 4~  After blocking with  10% normal rat serum in 
PBS-Tween,  LNC  supernatants  were  incubated  at  4~  over- 
night. Plates were washed with PBS-Tween, and then incubated 
with  biotin-conjugated-detection  anti-mouse  IL-4  rat  mAb, 
which was revealed with streptavidin-peroxidase conjugate and 
ABTS.  Optical densities were measured at 405  nm.  Cytokines 
concentrations were  calculated using the  linear portion of the 
curve obtained with recombinant standards run on each ELISA 
plate and expressed in AU/ml. 
Statistical Analysis.  Differences between groups were analyzed 
using Student's t-test and Mann-Whitney test. Equivalence be- 
tween treatments was determined by correlation anal/sis. Signifi- 
cance was admitted at P <0.05. 
Results 
Rabies SAg Induces a Long-term Increase of the Influenza-spe- 
cific Antibody  Response,  in  BALB/c  (V[36+)  but  Not  in 
BALB/D2 (V~6-) Mice.  Rabies SAg functions as a  SAg 
in BALB/c mice, activating T  lymphocytes bearing a V136 
chain, but not in c0ngenic BALB/D2 lacking V[36 T  lym- 
phocytes (6). The effect of rabies SAg on the antibody re- 
sponse to influenza immunization was compared m  BALB/c 
(V[36+)  and BALB/D2  (V[~6-)  mice. For both strains of 
mice,  the  influenza-specific whole antibody response  was 
followed in two experimental groups. One group received 
a  single injection of inactivated influenza virus (irrfluenza- 
injected mice), the second group received the same dose of 
inactivated influenza virus mixed with rabies SAg (SAg + 
influenza-injected mice). 
As shown in panel A  of Fig. 1, rabies SAg had a stimula- 
tory effect on  the  influenza-specific antibody response  in 
BALB/c mice. This effect was very rapid, occuring during 
the first week. The antibody response plateau was reached 
2  wk sooner in SAg +  influenza-injected mice (d14) than 
in  influenza-injected mice  (d30).  The  sfimulatory  effect 
was long-lasting, since the whole antibody response in SAg 
+  influenza-rejected mice  remained  10- to 3-fold higher 
than  that  observed in  influenza-injected mice  during  the 
80-d observation period. In contrast, as shown in the panel 
B  of Fig. 1, SAg treatment did not significantly enhance the 
influenza-specific antibody response in BALB/D2 mice, as 
expected. Analysis of the anti-influenza lgG and IgM (data 
not shown)  did not yield any difference either. BALB/D2 
mice  developed  an  influenza-specific  antibody  response 
comparable to the BALB/c one, and had been properly in- 
jected with  SAg, since  NC-specific antibodies developed 
(data not shown). These results suggest that rabies SAg ad- 
juvant effect is not  dependent upon  antigenic recognition 
ofrabies-NC or direct activation ofB lymphocytes. On the 
contrary,  they strongly support the hypothesis that V[3  T 
cell-dependent SAg recognition plays a key rote. 
Previous studies indicated that mineral or vegetal adju- 
vants can amplify preferentially, if not exclusively, IgG1 or 
IgG2a antibodies (12,  t3).  We investigated whether rabies 
SAg modified the  pattern  of IgG  isotypes or  the  Ig sub- 
classes  of the  influenza-antibody responses.  The  distribu- 
tion oflgM, IgG1, IgG2a, IgG2b, and whole IgG of influ- 
enza-specific  antibodies  were  measured  in  the  serum  of 
rabies  SAg  +  influenza  injected  and  influenza-injected 
mice  (data not shown).  Rabies SAg stimulated all the iso- 
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Figure I.  A single rejection of rabies SAg con- 
comitantly with  influenza antigen induces a very 
early, long-term increase of influenza-specific  anti- 
body response in BALB/c mice hut has no effect in 
BALB/D2 mice. Effect of SAg on the whole anti- 
body response to influenza in  (A) BALB/c  mice 
and (B) in BALB/D2 mice, lacking T lymphocytes 
expressing the SAg recognition element (V~6). In- 
fluenza-specific antibody titers, expressed in AU/ 
ml, were measured every week, during 3 mo for 
BALB/c mice and 3 wk for BALB/D2 mice, in se- 
rum from mice receiving either SAg +  influenza 
(ll) or influenza alone (C)) at day 0. Data presented 
are the mean titers +  SEM of 4-6 mice per group. 
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Figure  2.  Adjuvant effect of rabies SAg on sec- 
ondary  influenza-specific protective  antibody  re- 
sponse. Comparison of the protective HI antibodies 
response in BALB/c mice having received at day 0 
influenza alone (gray bars) or SAg + influenza (black 
bars), followed by a secondary injection for all mice 
with influenza on day 90 (Influenza boost). HI anti- 
bodies titers, expressed in HIU/ml, measured for 3 
mo after primary injection are presented on the left 
part of the scheme (left scale 0-200 HIU/ml), and 
those  measured 2  wk  after a boost  of influenza 
alone are presented on the right part (right scale 
0-2,000 HIU/ml). Data presented are the mean ti- 
ters -+ SEM of 4-6 mice per group. An asterisk in- 
dicates significant  difference, at P <0.05, found be- 
tween the two groups of mice. 
types with a slightly higher increase of the IgG1 antibodies. 
Therefore, rabies SAg does not seem to preferentially acti- 
vate  any  particular  class  or  isotype  of influenza-specific 
antibodies,  and  instead  seems  to  amplify  the  pattern  of 
isotypes and subclasses already skewed by the influenza vac- 
cination. 
The adjuvant effect of rabies SAg was found to be dose 
dependent and to be affected by the immunization sched- 
ule (data not shown).  For example, the same dose of SAg 
that  enhanced  antibody  response  when  given  simulta- 
neously with  the influenza virus failed to significantly en- 
hance the antibody response when given 3 d before immu- 
nization (data not shown). However, SAg given 3  d before 
the  influenza virus  was  efficient if the  concentration  was 
10-fold higher. 
The Secondary Immune  Response  to Influenza  Is Increased  in 
Mice Primed with Influenza and Rabies SAg.  Hemagglutinin 
(HA) is a highly immunogenic surface protein of the influ- 
enza  virus.  It  is  the  major  antigen  inducing  antibodies 
which inhibit hemagghitination and neutralize the infectiv- 
ity of the virus. Good correlation is observed between pro- 
tection against influenza and the titers ofhemagglutination- 
inhibiting antibodies  (HI  antibodies).  The  time  course  of 
the HI antibody concentration was compared in SAg +  in- 
fluenza- and influenza-injected mice at 7,  15, 21, and 90 d 
after immunization.  At  90  d,  mice  from  the  two  groups 
were  boosted with influenza alone.  Serum  collected 14  d 
after the boost was analyzed for HI antibodies (Fig. 2). Ra- 
bies SAg-treated mice showed significantly greater titers of 
HI antibodies during the observation period with a peak on 
d21, indicating that influenza immunization associated with 
the rabies SAg has a greater protective capacity. Moreover, 
this  twofold  increase in  HI  antibodies observed between 
the  two  groups was  maintained after a  boost of influenza 
alone on day 90. These results show that rabies SAg can in- 
crease  antibody level not  only in  a  primary but  also  in  a 
secondary response to an associated antigen. They also in- 
dicate that the rabies SAg adjuvant effect on the antibody 
response  is  a  long-lasting one,  since  improvement  of the 
secondary response can be obtained without  a  second in- 
jection of SAg. Taken together,  these observations clearly 
establish that rabies SAg is an early and long-lasting immu- 
nostimulant of the  influenza antibody response  especially, 
the protective response. 
A  boost  with  SAg  alone  was  also  performed  to  test 
whether SAg adjuvant can recruit antigen-specific antibod- 
ies in the absence of recall antigen. 3  mo after the second- 
ary influenza injection, both groups of mice were injected 
with  SAg alone.  NC-specific and  influenza-specific anti- 
bodies were measured for 3 wk after the secondary SAg in- 
jection (data not shown).  No increase in influenza-specific 
antibodies could be observed. The last result indicates that 
the  adjuvant  effect  requires  the  coadministration  of SAg 
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Figure 3.  In vivo rabies SAg treatment enhances both spontaneous and 
influenza-specific proliferation  of LNC  from  BALB/c  mice  but  not 
BALB/D2 mice. Spontaneous proliferation obtained in cultures without 
stimulus (= 0 p~g/ml of influenza virus) and influenza-specific  prolifera- 
tion obtained in cultures with 0.001-1 ~g/ml of  inactivated influenza vi- 
rus were measured in LNC collected from BALB/c mice (left panels) or 
from BALB/D2 mice (right panels) 3 d after receiving either influenza 
alone (gray bars) or SAg + influenza (black bars). Results expressed in cpm 
X  10  -3 were obtained with pooled LNC from two mice in each group 
and are representative of two separate experiments. A similar pattern was 
observed 5 and 7 d after injection. Thymidine incorporation in  LNC 
cultures from mice injected with PBS or SAg alone did not exceed 1 X 
103 cpm. 
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reactive epitopes with influenza virus antigens. 
Lymphocyte  Responses  to  Influenza  Virus Are  Increased  in 
SAg-treated BALB/c  (V~6+),  but Not in BALB/D2  (V~6-) 
Mice.  Having shown that rabies SAg treatment enhances 
the influenza response at the  antibody level, we next ad- 
dressed  the  question  of whether  rabies  SAg  affected  the 
lymphocyte response. We compared the ability oflympho- 
cytes from SAg +  influenza- or influenza-injected mice to 
proliferate either without added stimulus (spontaneous pro- 
hferation)  or with  three  different concentrations  of influ- 
enza  (influenza-specific proliferation).  Two  controls  were 
included:  mice  receiving  SAg  or  PBS  alone.  Draining 
popliteal LN were removed 1, 3, 5, and 7 d after the treat- 
ment,  and LNC  were  treated  with  or without  influenza. 
Results are presented for day 3 in Fig. 3. Without stimulus 
(0  b~g/ml of influenza),  LNC of SAg-treated BALB/c in- 
corporated 5  ￿  103  cpm more than LNC from mice re- 
ceiving influenza alone.  This difference was even stronger 
7  d  after  the  injection  (3  ￿  104  cpm  more  than  the 
[3H]thymidine incorporation of LNC from mice receiving 
influenza alone, data not shown). This indicates that spon- 
taneous proliferation was enhanced by the SAg treatment. 
Regarding  the  influenza-specific  LNC  proliferation,  it 
can be seen that whatever the  concentration  of influenza 
(0.0l-1  p,g/ml), [3H]thymidine incorporation was five- to 
threefold higher in LNC from mice injected with SAg + 
influenza  than  from mice  injected  with  influenza  alone. 
This increase is evident as early as day 3 (Fig. 3), and main- 
tained until 7 d after injection (data not shown). Taken to- 
gether,  the data clearly indicate  that rabies SAg stimulates 
the  cellular  response,  and  suggest  that  rabies  SAg  could 
have enhanced  the  number of LNC  recruited in vivo by 
the influenza virus. 
In contrast, as shown in the right panel of Fig. 3, rabies 
SAg treatment did not amplify the [3H]thymidine incorpo- 
ration of LNC from BALB/D2, indicating, as already stated 
for the antibody response, that the mechanism of the rabies 
SAg  stimulating  activity  correlates  with  the  presence  of 
V~36 T  cells. The absence of any increase in proliferation in 
BALB/D2  LNC  raises  two  issues.  First,  since  B  cells  of 
BALB/c  and BALB/D2 are identical, the absence of a SAg 
stimulatory effect on BALB/D2 LNC strongly suggests that 
LNC proliferation did not result from direct B  cell  activa- 
tion. Secondly, the possibility that the increase of [3H]thy- 
midine  incorporation  in  SAg-treated  mice  resulted  from 
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Figure  4.  In vivo rabies SAg 
treatment  enhances  IL-2 and 
IL-4 production by  influenza- 
restimulated BALB/c LNC. In 
vitro IL-2 (left panels) and IL-4 
(right panels) were compared in 
LNC cultures of BALB/c mice 
injected with SAg  +  influenza 
(')  and  influenza (lines). LN 
were collected 3, 5, and 7 d after 
treatment. IL-2  was measured by 
CTLL-2  cell prohferation and 
IL-4 by capture ELISA. These 
data are  representative of two 
separate experiments. % of positive  wells 
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Figure 5.  In vivo rabies SAg treatment enhances 
the number of influenza-primed T cells within the 
V[~6+ population. LDA were performed with pu- 
rified V[~ T cells (,4) or V~10 T cells (g) isolated 
from LN collected 7 d after injection, of mice re- 
ceiving either SAg +  influenza (IJ) or influenza 
alone (O). 20 replicate wells were seeded for each 
concentration of purified V~ T ceils, and 20 repli- 
cate we~ls without T cell as control. A well was 
considered positive when  IL-2  production,  de- 
tected in its supematant, was at least three times 
higher than the average of controls. These data are 
representative of two separate experiments. 
the  administration  of two  antigens  (SAg and influenza)  is 
excluded. 
In  Vivo Rabies SAg  Treatment Enhances  In  Vitro IL-2 and 
IL-4  Production  by  Influenza  Restimulated  BALB/c  LNC. 
T  lymphocytes are most probably responsible for the influ- 
enza specific proliferation of LNC observed above. To in- 
vestigate this question and test whether in vivo SAg treat- 
ment enhances interleukin production, IL-2 and IL-4 were 
measured  in  the  supernatants  of LNC  from BALB/c re- 
ceiving SAg  +  influenza  or influenza  alone  in  vivo,  and 
then cultured in vitro with increased concentrations of in- 
fluenza.  IL-2 production  (Fig.  4,  left panels)  is  shown  for 
LNC  collected  on days 3,  5,  and  7  after  the  injection  of 
SAg +  influenza  or influenza  alone.  In response  to influ- 
enza restimulation,  IL-2 production is higher, occurs earlier 
and requires lower doses of antigen in LNC of SAg-treated 
mice than  in LNC of mice injected  with  influenza alone. 
Table  1.  Influenza-primed T Cells Frequencies within Vfl Purified 
Populations 
Purified  Confidence 
Injection  population  Frequency +_ SE  interval  95% 
1~cell Nb ￿  10 -3 
a  Influenza  V136+  1/41.8 +  0.2  [20.7-79] 
b  Rabies SAg  id  1/8.6 -+ 0.2  [6.4-11.4] 
+  influenza 
c  Influenza  V[310+  1/70.1  -+ 6  [41.9-112.3] 
d  Rabies SAg  id  1/49.t  -+ 3.1  [22.3-142.6] 
+  influenza 
Data described in Fig. 5 were regressed as the log of the percentage of 
nonresponder wells against the number of cells/well, and frequencies 
estimated as the reciprocal of  the number of cell corresponding to 37% 
of nonresponders. Frequencies are  presented  +-  SE  and  with  their 
ranges (95% CI), calculated using the least square method of regre~ion. 
Significances, assessed by variance analysis, were: (a/b) P = 0.004; (a/c) 
P = 0.09; (c/d) P = 0.6. 
For example, when restimulated with 1 wg/ml of influenza 
antigen, LNC of SAg-treated mice produced enough IL-2 
to induce a strong prohferation of CTLL-2 (10 ￿  103 cpm) 
whereas  LNC of mice injected with influenza  alone pro- 
duced IL-2 levels that are undetectable by the CTLL-2 as- 
say. 7 d after the in vivo injections,  1,000-fold more influ- 
enza  antigen  was  necessary  in  vitro  to  induce  detectable 
levels of IL-2 in LNC of mice primed with influenza alone 
compared  to  those  primed  with  SAg  +  influenza.  Simi- 
larly,  but  at  lower  levels,  IL-4  production  (Fig.  4,  right 
panel)  of LNC  taken  from SAg +  influenza--treated  mice 
was  also  significantly  higher  than  that  observed  in  LNC 
from mice receiving influenza alone.  The kinetics of IL-4 
influenza-specific  production  is,  as  expected,  delayed  in 
comparison  with  IL-2  production.  Together  these  data 
clearly indicate that rabies SAg treatment results in a higher 
cytokine  production  in  response  to  the  antigen,  and 
strongly suggest that mainly T  lymphocytes account for the 
influenza-specific proliferation. 
Rabies SAg Spedfically Increases the Number of Influenza-primed 
Vfl6 T  Cells.  The  next  question  addressed  was  whether 
rabies  SAg specifically increases  the  number  of influenza- 
primed  V~6  T  cells.  To  answer  this,  we  quantified  the 
number of influenza-primed T  cells within the V~36 T  cells 
population.  This was measured by a LDA of purified V~6 
T  cells from LNC of BALB/c mice receiving SAg +  influ- 
enza or influenza alone. As a control, frequencies of influ- 
enza-primed  V~10  T  cells,  which  are  not  recognized by 
the  rabies  SAg (6),  were  analyzed in the same  conditions. 
The  percentage  of positive  -wells (out  of 20)  versus  the 
number of cells  (￿  10  -3) per well are presented in Fig.  5. 
The  estimated frequencies  +  SE and the  95%  confidence 
interval  (Table  1)  were then calculated for each  group,  as 
described in the legend. Within the V[36 T  cell population, 
the  frequency  of influenza-primed  T  cells  is  nearly  five 
times  higher when  mice have been injected  with  SAg + 
influenza (1/8.6  ￿  103) compared with rrfice injected with 
influenza alone (I/41.8  ￿  I03). By comparison, within the 
V[310  T  cell  population  the  difference  of frequencies  is 
1628  Rabies SAg as a Vaccine Adjuvant much smaller (1/49.1  ￿  103 compared to  1/70.1  ￿  103), 
and not significant. These results show that the rabies SAg, 
during establishment of the primary immune response, in- 
creases  specifically the number of influenza-specific T  cells 
bearing the recognized V~6 element. 
Discussion 
In  this  study,  we  present  evidence  that  rabies  NC, 
through its SAg properties, clearly stimulates both at the T 
and B lymphocytes level, an associated, unrelated immune 
response. T  cell proliferation and cytokine production are 
increased, as well as specific antibody secretion. This latter 
result is observed both during the primary and secondary 
response and, without modification of their characteristics 
such as isotypes or subclasses. We had found previously that 
rabies  SAg targets the Vl~6-expressing CD4 + T  lympho- 
cytes in mice (6).  In the present study, we show that the 
adjuvant effect was not observed in congenic mice miming 
VI36 T  lymphocytes, and moreover, that within the influ- 
enza responding T  cells,  it is primarily the VI36+ popula- 
tion which is increased. This indicates that g136 T lympho- 
cytes play a key role in  the augmentation of the  specific 
immune response and strongly supports our hypothesis that 
the  SAg property of NC  is  responsible for its  enhancing 
mechanism. 
Liu et al. (14) described, at the clonal level, how SAg and 
conventional antigen trigger two distinct activation path- 
ways. The signal provided by the SAg is described as acting 
in synergy with the antigenic one resulting in stronger pro- 
liferation and cytokines release. Applying this clonal study 
to our model, the coinjection of influenza antigen and ra- 
bies  SAg,  we  can  propose a  cascade  mechanism  starting 
with the rabies SAg property to provide an additional acti- 
vation signal to T  cells. In this hypothesis, the first target of 
coinjected rabies  SAg  would  be  the  influenza-specific T 
cells bearing a VI36 TCR, explaining the absence of effect 
observed in congenic V136-negative mice. The extra-signal 
brought by rabies SAg on these cells would augment their 
frequency, as indeed observed in the LDA experiment. In a 
second step, the increased amount of cytokines released in 
the environment would favor the expansion of  many influ- 
enza-specific T  cells,  irrespective of their VI3 element, as 
reflected by the very strong enhancement of proliferation 
and cytokines production observed with the total LN cells. 
The overall increase in T  cells number and released cyto- 
kines would then provide a greater help toward activated B 
cells and Ig production, as observed in the specific antibod- 
ies assays. Finally, the higher number of primed T  and B 
lymphocytes might result in the enlargement of the num- 
ber  of memory cells,  since  we  have observed that  rabies 
SAg modulates the secondary response as well. 
It is well documented that SAg can induce in vitro poly- 
clonal B cell proliferation and differentiation, resulting in lg 
production.  This property has been described in vitro for 
nearly all viral,  bacterial or mycoplasm SAg (15-17). How- 
ever regarding their effect in vivo and  on a  specific im- 
mune response, two kinds of SAg can be distinguished. In 
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addition to the rabies SAg (this study and reference 8), the 
capacity  to  stimulate  antibody  production  is  also  docu- 
mented with the Mycop/asma-derived SAg (the Mycoplasma 
arthritidis  mitogen, MAM),  which was  found to stimulate 
polyclonal IgM production and specific anti-OVA lgG (15, 
18).  However, other SAg are devoid of this  capacity, in 
particular the bacterial SAg,  the Staphylococcus enterotoxin 
type B, SEB, which inhibits in vivo antigen-specific anti- 
body responses 09, 20). It seems then that SAg T-B bridg- 
ing is not sufficient in vivo to trigger B  cells  to produce 
antigen-specific antibodies  and  that  additional  factors are 
involved. The nature of the cytokines produced upon SAg 
activation could be one of these factors, since they play a 
major role in modulating the capacity of lymphocytes to 
produce lg.  For example, it is known that high IL-2 and 
IFN-~/ production drives  the  immune  response toward a 
cytotoxic response rather than an antibody response. More- 
over, bacterial SAg, such as SEB (Staphylococcus aureus  en- 
terotoxin of type B)  and TSST-1  (toxic shock syndrome 
toxin of type 1), were found to be strong IL-2 inducers (5, 
21-23), whereas MAM and rabies SAg--reactive T  cells se- 
crete  lower levels  of IL-2  and  no  IFN-"y  (18).  Another 
common  feature  between  MAM  and  rabies  SAg  is  that 
they are relatively weak T lymphocyte mitogens compared 
to bacterial SAg (15). Other arguments support the premise 
that these properties are involved in the capacity of SAg to 
enhance antibody production or not. First, addition of IL-2 
to MAM-activated cultures diminishes drastically the ability 
of these  cells  to  produce  lgG  (15).  Second,  the  use  of 
suboptimal doses  (100-fold lower than those required for 
proliferation)  of bacterial  SAg  restores  their  capacity  to 
stmaulate Ig production (24).  In these experiments, the re- 
lationship between Ig induction and mitogenic effect is in- 
versely proportional.  Therefore, it  is  likely that bacterial 
SAg capacity to diminish antibody responses in vivo may 
be related to their high mitogen activity for T  lymphocyte 
and strong IL-2 inducer capacity. Conversely, the ability of 
MAM  and rabies SAg to stimulate an antigen-specific re- 
sponse in vivo may be related to the opposite properties: 
weak T lymphocyte mitogen and weak IL-2 inducer, com- 
pared to bacterial SAg. 
Inhibition  of antigen-specific  antibody  responses  ob- 
served in vivo with most bacterial SAg could be due to an- 
other factor, the anergy or nonresponsiveness that most of 
them induce. It is well known that SEB, for example, ex- 
erts pleiotropic effects in vivo, causing first  a rapid expan- 
sion of the V{3 T  cells recognized 36-92 h  after injection, 
followed 4--5 d after injection by a clonal deletion and/or 
an anergy state of the previously expanded T  lymphocytes 
(25).  The SAg capacity to first activate and then anergize 
entire T  lymphocyte subsets  may explain the puzzling re- 
suits  obtained  when  varying the  schedule  of immuniza- 
tions.  For example, SEB given long enough after priming 
(at least 2 d) boosted the response or had no effect if given 
at  the  time  of priming  or  before  the  antigen  SEB  sup- 
pressed the immune response (19,  20). Since NC is a SAg, 
it is surprising that the rabies SAg is a stimulant when given 
at the time of priming (or before), and, especially that it has a long lasting effect. Anergy is defined as an absence of re- 
sponse of T  cells to a second stimulation with the same an- 
tigen (26). We have shown here that the T  cells primed by 
influenza and NC proliferated and produced more IL-2 to 
an  in  vitro  recall  of antigen.  Similarly,  in  vivo,  another 
study (8) showed that a recall of antigen (KLH) with NC in 
mice already primed with NC  +  KLH did not inhibit the 
antigenic response, but boosted it. These data confirm that 
rabies  SAg, differing from most other  SAgs,  does  not in- 
duce  anergy  in  vivo.  Anergy  is  thought  to  be  induced 
when a stimulus is excessive,  not associated with the right 
cosignals, and/or the stimulated cells are not mature enough. 
The  absence  of anergy induced by NC  fits  well with  the 
unique  properties  of rabies  SAg as  a  weak  T  lymphocyte 
mitogen, and activator of already differentiated B  cells  and 
primed T  cells (5). 
It  therefore  appears  that,  despite  the  capacity  of every 
SAg to bridge together T  and B  cells,  only a special class of 
SAg has adjuvant properties.  These  SAg must be weak  T 
lymphocyte-mitogens,  and  low  IL-2  inducers,  and  must 
not trigger anergy of the cells they expand. Currently, only 
two SAg fullfill  these criteria: rabies NC and MAM. Bacte- 
rial SAg, in contrast, are suppressors of in vivo antigen-spe- 
cific antibody production because of their excessive activa- 
tion of the immune system. 
Because of the unusual T-B interactions that rabies SAg 
may create,  they can be suspected of reactivating T  and B 
lymphocytes directed  to auto-antigens.  In a  model of au- 
toimmune  disease where the recognition of the  auto-anti- 
gen is restricted to a limited set of V[3 T  lymphocytes, it has 
been described that injection of SAg activating these crucial 
V[3  T  lymphocytes  stimulates  autoimmune  relapse  (27). 
Our results indicate that no increase of influenza antibodies 
could be obtained when NC was injected without antigen, 
showing that NC alone was unable to recall a memory re- 
sponse.  It seems,  therefore,  that the risk linked to any po- 
tent  immunostimulant  of activating  resting  pathogenic  T 
cells is minimal with rabies SAg. In this respect, it is possi- 
ble that the relative weakness  of NC  is once again an ad- 
vantage. 
In conclusion,  we  propose  that  rabies  SAg could be  a 
good candidate as adjuvant in vaccine design because of its 
capacity  to  stimulate  specific  antibody  production  over  a 
long period and its ability to enhance the establishment of a 
memory response. Moreover, except for HIV-infected pa- 
tients  (28),  no  V[3  T  lymphocyte  deletion  has  been  re- 
ported so far in humans,  and SAg activation is not MHC 
restricted.  It  could  thus  be  the  first  of a  new  class  of 
T-mediated adjuvants. 
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